Showing results (661-670 of 728) with videos related to
Sort By:
Pageof 73
American Journal of Nephrology|November 21, 2022
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor DanicopanSteven D Podos, Howard Trachtman, Gerald B Appel, et al.Pediatric Nephrology (Berlin, Germany)|April 11, 2015
An international consensus approach to the management of atypical hemolytic uremic syndrome in childrenChantal Loirat, Fadi Fakhouri, Gema Ariceta, et al.JCO Precision Oncology|August 18, 2025
Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS StudyDebu Tripathy, Joanne L Blum, Hong Zhang, et al.Endoscopy|March 1, 1997
Comparison between esophageal Wallstent and Ultraflex stents in the treatment of malignant stenoses of the esophagus and cardiaG Dorta, J Binek, A L Blum, et al.Gastroenterology|March 26, 1999
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adultsP Michetti, C Kreiss, K L Kotloff, et al.Journal of Clinical Medicine|July 14, 2023
Persistent Increase in Serum Ferritin Levels despite Converting to Permanent Vascular Access in Pediatric Hemodialysis Patients: Pediatric Nephrology Research Consortium StudyAli Mirza Onder, Md Abu Yusuf Ansari, Fang Deng, et al.Cancer Medicine|March 28, 2018
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancerFrankie Ann Holmes, Beth A Hellerstedt, John E Pippen, et al.The Oncologist|June 15, 2023
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II StudyJennifer K Litton, J Thaddeus Beck, Jason M Jones, et al.American Journal of Nephrology|November 24, 2022
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 StudiesCarla Nester, Gerald B Appel, Andrew S Bomback, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJavier Cortes, Linda Vahdat, Joanne L Blum, et al.Pageof 73